FLUCYTOSINE
ANTIFUNGALS-SYSTEMIC·CANDIDAL URINARY TRACT INFECTION·+2
AHP
Indication
Systemic cryptococcosis treatment adjunct
Systemic cryptococcosis is an invasive fungal infection caused primarily by encapsulated yeasts of the *Cryptococcus neoformans* or *Cryptococcus gattii* species complexes, which initiate infection in the respiratory tract following inhalation and hematogenously disseminate to other organ systems. Read more about Systemic cryptococcosis treatment adjunct
13 drugs 13 manufacturers
Drugs that treat it
Common Systemic cryptococcosis treatment adjunct therapies.
FLUCYTOSINE
ANTIFUNGALS-SYSTEMIC·CANDIDAL URINARY TRACT INFECTION·+2
BRYANT RANCH PR
FLUCYTOSINE
ANTIFUNGALS-SYSTEMIC·CANDIDAL URINARY TRACT INFECTION·+2
AUROBINDO PHARM
FLUCYTOSINE
ANTIFUNGALS-SYSTEMIC·CANDIDAL URINARY TRACT INFECTION·+2
Avet Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Systemic cryptococcosis treatment adjunct preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSystemic cryptococcosis is an invasive fungal infection caused primarily by encapsulated yeasts of the *Cryptococcus neoformans* or *Cryptococcus gattii* species complexes, which initiate infection in the respiratory tract following inhalation and hematogenously disseminate to other organ systems.
It predominantly affects individuals with cell-mediated immune deficiencies, such as people living with advanced HIV disease, solid organ transplant recipients, and those receiving immunosuppressive therapies, with a critical predilection for the central nervous system presenting as subacute meningoencephalitis.
Defining clinical and pathophysiological manifestations include elevated intracranial pressure, persistent headache, altered mental status, pulmonary infiltrates, and extrapulmonary lesions in the skin, bones, or viscera driven by fungal polysaccharide capsule accumulation and host inflammatory injury.
In the context of "systemic cryptococcosis treatment adjunct," the clinical state represents systemic or disseminated cryptococcal disease requiring supplementary therapeutic modalities administered alongside primary antifungal regimens to enhance fungal clearance or mitigate refractory pathology.
- nih.gov
Systemic cryptococcosis is an invasive fungal infection caused primarily by encapsulated yeasts of the *Cryptococcus neoformans* or *Cryptococcus gattii* species complexes, which initiate infection in the respiratory tract following inhalation and hematogenously disseminate to other organ systems It predominantly affects individuals with cell-mediated immune deficiencies, such as people living with advanced HIV disease, solid organ transplant recipients, and those receiving immunosuppressive the...
- creative-biolabs.com
It predominantly affects individuals with cell-mediated immune deficiencies, such as people living with advanced HIV disease, solid organ transplant recipients, and those receiving immunosuppressive therapies, with a critical predilection for the central nervous system presenting as subacute meningoencephalitis
- merckmanuals.com
Defining clinical and pathophysiological manifestations include elevated intracranial pressure, persistent headache, altered mental status, pulmonary infiltrates, and extrapulmonary lesions in the skin, bones, or viscera driven by fungal polysaccharide capsule accumulation and host inflammatory injury
- oup.com
Defining clinical and pathophysiological manifestations include elevated intracranial pressure, persistent headache, altered mental status, pulmonary infiltrates, and extrapulmonary lesions in the skin, bones, or viscera driven by fungal polysaccharide capsule accumulation and host inflammatory injury
- hiv.gov
In the context of "systemic cryptococcosis treatment adjunct," the clinical state represents systemic or disseminated cryptococcal disease requiring supplementary therapeutic modalities administered alongside primary antifungal regimens to enhance fungal clearance or mitigate refractory pathology
- nih.gov
In the context of "systemic cryptococcosis treatment adjunct," the clinical state represents systemic or disseminated cryptococcal disease requiring supplementary therapeutic modalities administered alongside primary antifungal regimens to enhance fungal clearance or mitigate refractory pathology
Personalize your experience
Follow Systemic cryptococcosis treatment adjunct and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.